DONORS (Donation Network to Optimise Organ Recovery Study): Study protocol to evaluate the implementation of an evidence-based checklist for brain-dead potential organ donor management in intensive care units, a cluster randomised trial.

Introduction: There is an increasing demand for multi-organ donors for organ transplantation programmes. This study protocol describes the Donation Network to Optimise Organ Recovery Study, a planned cluster randomised controlled trial that aims to evaluate the effectiveness of the implementation of an evidence-based, goal-directed checklist for brain-dead potential organ donor management in intensive care units (ICUs) in reducing the loss of potential donors due to cardiac arrest.

Methods And Analysis: The study will include ICUs of at least 60 Brazilian sites with an average of ≥10 annual notifications of valid potential organ donors.

Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial.

Background: The dose equivalence of commonly used commercial preparations of botulinum toxin type A, Dysport (abotulinumtoxinA [ABO] 500 U, Ipsen Biopharm Limited, Wrexham, United Kingdom) and Botox (onabotulinumtoxinA [ONA] 100 U, Allergan, Irvine, CA), remains unclear.

Objective: We sought to evaluate the field effect for ABO and ONA at dose equivalences of 2.5:1.

Side-by-side comparison of areas with and without cellulite depressions using magnetic resonance imaging.

Background: Cellulite is characterized by alterations in the relief of the skin surface. Magnetic resonance imaging (MRI) is recognized as a reliable technique for measuring adipose volume according to body site and for the visualization of the subcutaneous structures.

Objective: To compare subcutaneous tissue in areas with and without cellulite on the buttocks of same subjects using a noninvasive technique.

Blind multicenter study of the efficacy and safety of injections of a commercial preparation of botulinum toxin type A reconstituted up to 15 days before injection.

Background: It is recommended that attention be given to the shelf life of botulinum toxin type A (BT-A) after its reconstitution.

Objective: To assess the efficacy and safety of 500 U of BT-A after reconstitution up to 15 days after injection.

Material And Methods: BT-A vials were diluted 15 days, 8 days, and 8 hours before injection.

A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A.

Background: The determination of the action halos of botulinum toxin type A aids in targeting specific muscles and/or sweat glands, thereby preventing the occurrence of side effects.

Objectives: The objective of this study was to compare the action halos of two commercial preparations of botulinum toxin type A, Dysport (Ipsen, Slough, UK) and BOTOX (Allergan, Irvine, CA).

Material And Methods: Eighteen volunteers received applications of both products into randomized sides of the frontalis muscle.